Zepzelca (lurbinectedin)
pCPA File Number:
22128
Negotiation Status:
Negotiations were not pursued
Indication(s):
Stage III or metastatic small cell lung cancer (SCLC) in adult patients who have progressed on or after platinum-containing therapy
Sponsor/Manufacturer:
Jazz Pharmaceuticals Canada Inc.
CDA-AMC Project Number:
PC0281-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded: